

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

HCC1500

RRID:CVCL_1254

Type: Cell Line

Proper Citation

ATCC Cat# CRL-2329, RRID:CVCL_1254

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1254

Proper Citation: ATCC Cat# CRL-2329, RRID:CVCL_1254

Description: Cell line HCC1500 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12800145](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30787054](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1500

Synonyms: HCC-1500, Hamon Cancer Center 1500

Cross References: BTO:BTO_0006441, CLO:CLO_0003639, EFO:EFO_0001172, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-2329, BioSample:SAMN03471865, BioSample:SAMN10988466, cancercelllines:CVCL_1254, Cell_Model_Passport:SIDM00879, Cosmic:687476, Cosmic:904365, Cosmic:1018471, Cosmic:1047709, Cosmic:1136374, Cosmic:1287885, Cosmic:1603203, Cosmic:1935006, Cosmic:1995424, Cosmic:2165022, Cosmic:2750522, Cosmic-CLP:1303900, DepMap:ACH-000349, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1303900, GEO:GSM217574, GEO:GSM219982, GEO:GSM344376, GEO:GSM344426, GEO:GSM350538, GEO:GSM459706, GEO:GSM783971, GEO:GSM887040, GEO:GSM888110, GEO:GSM984232, GEO:GSM1008899, GEO:GSM1053690, GEO:GSM1214571, GEO:GSM1374500, GEO:GSM1669847, IARC_TP53:22812, LiGeA:CCLE_498, LINCS_HMS:50579, LINCS_LDP:LCL-1325, PharmacDB:HCC1500_478_2019, PRIDE:PXD030304, Progenetix:CVCL_1254, SLKBase:3524, Wikidata:Q54881583

ID: CVCL_1254

Vendor: ATCC

Catalog Number: CRL-2329

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260829T233628+0000

Ratings and Alerts

No rating or validation information has been found for HCC1500.

No alerts have been found for HCC1500.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Przanowska R, et al. (2026) IL-6R blockade with tocilizumab disrupts pericyte- and tumor cell-driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer. bioRxiv : the preprint server for biology.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. Cell chemical biology, 33(6), 785.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Przanowska RK, et al. (2024) Patient-derived response estimates from zero-passage organoids of luminal breast cancer. *Breast cancer research : BCR*, 26(1), 192.

Choi BH, et al. (2022) Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. *Cell reports*, 38(3), 110278.

Aka Y, et al. (2021) Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. *The international journal of biochemistry & cell biology*, 137, 106028.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. *Cell*, 181(7), 1596.

Cotul EK, et al. (2020) Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. *Cancers*, 12(9).

Mabe NW, et al. (2020) G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. *Cell reports*, 33(5), 108341.

Sreekumar S, et al. (2020) Differential Regulation and Targeting of Estrogen Receptor ?? Turnover in Invasive Lobular Breast Carcinoma. *Endocrinology*, 161(9).

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Harris IS, et al. (2019) Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. *Cell metabolism*, 29(5), 1166.

Hirukawa A, et al. (2019) Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. *Cell reports*, 29(2), 249.

Hafner M, et al. (2019) Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. *Cell chemical biology*, 26(8), 1067.

Guan J, et al. (2019) Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. *Cell*, 178(4), 949.

Wang T, et al. (2018) JAK/STAT3-Regulated Fatty Acid ??-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. *Cell metabolism*, 27(1), 136.

McMillan EA, et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. *Cell*, 173(4), 864.